Long‐term effect of first‐line injectable multiple sclerosis treatments: Input of a time‐dependent propensity score-Reference-Cited by-同舟云学术

Long‐term effect of first‐line injectable multiple sclerosis treatments: Input of a time‐dependent propensity score

Published:2020-11-11 Issue:12 Volume:29 Page:1680-1688
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Lefort Mathilde¹²^ORCID,Foucher Yohann³⁴,Lenain Remi³⁵,Vukusic Sandra⁶⁷⁸⁹,Edan Gilles²¹⁰,Leray Emmanuelle¹²¹¹

Affiliation:

1. Pharmaco‐epidemiology and health Services Research Department Rennes University, EHESP, REPERES – EA 7449 Rennes France

2. Neurology Department Univ Rennes, CHU Rennes, Inserm, CIC 1414 [(Centre d'Investigation Clinique de Rennes)] Rennes France

3. Biostatistic Department INSERM UMR 1246 – SPHERE, Nantes University, Tours University Nantes France

4. Nephrology Department Nantes University Hospital Nantes France

5. Nephrology Department Lille University Hospital Lille France

6. Neurology Department Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro‐inflammation Bron France

7. Neurology Department Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292 Lyon France

8. Neurology Department Université de Lyon, Université Claude Bernard Lyon 1 Lyon France

9. Neurology Department Eugène Devic EDMUS Foundation against Multiple Sclerosis, State‐Approved Foundation Bron France

10. Neurology Department CHU Pontchaillou Rennes France

11. METIS Department EHESP French School of Public Health Rennes France

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5154

Reference39 articles.

1. Multiple sclerosis;Filippi M;Nat Rev,2018

2. LublinFD ReingoldSC CohenJA et al.Defining the clinical course of multiple sclerosis The 2013 Revisions.2014.

3. HAS.BETAFERON 250 ‐ Transparency committee.2010.

4. HAS.Copaxone ‐ Avis de la commission.2002.

5. Intramuscular interferon beta‐1atherapy initiated during a first demyelinating event in multiple sclerosis;Jacobs L;J Med,2000